Breaking News

Charles River Forms Partnership With BioMotiv

Investing up to $10M in the company

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Charles River Laboratories has entered into a partnership with BioMotiv, committing to invest up to $10 million in the company. BioMotiv is the therapeutic accelerator company associated with The Harrington Project for Discovery & Development. Charles River will provide discovery and preclinical development services that will enable BioMotiv to advance discoveries sourced from academic research and non-governmental organizations into novel medicines. Charles River will be the preferred...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters